RE:RE:H.C. Wainwright Reiterates Buy Rating on Oncolytics Biotech Unfortunately over the years none of these analysts have been correct. The last years BT was running ONC he seemed to have pivoted to getting approval in Europe versus with the FDA. Because of BP influence over the FDA I believe they should have continued with this strategy. I am highly suspicious of the FDA overall intentions when it comes to drug approvals.